Rakovina Therapeutics

Press Releases & News Coverage

Press Releases

August 29, 2023: Interim Condensed Consolidated Statements of Financial Position

August 29, 2023: Management Discussion and Analysis

June 28, 2023: Rakovina Therapeutics Announces Results from 2023 Annual General Meeting

May 30, 2023: Management Discussion and Analysis

May 30, 2023: Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results and Provides Corporate Update

May 29, 2023: Rakovina Therapeutics Inc. Announces Closing of $1.5 Million Convertible Debenture Financing

May 1, 2023: Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture Financing

April 20, 2023: Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting

April 17, 2023: Rakovina Therapeutics to Present at the Emerging Growth Conference on April 19, 2023

Mar 30, 2023: Rakovina Therapeutics Inc. Announces Enhanced Liquidity and Investor Awareness Programs 

Mar 22, 2023: Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies

Jan 26, 2023: Rakovina Therapeutics Announces Presentation at the 6th Annual DDRinhibitors Summit

Nov 23, 2022: Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022

Nov 17, 2022: Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update

Nov 14, 2022: Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma

Oct 31, 2022: Rakovina Therapeutics Announces Preclinical Data Presentation at the 34th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Sept 28, 2022: Rakovina Therapeutics Announces Upcoming Scientific Conference Presentations

August 11, 2022: Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update

June 23, 2022: Rakovina Therapeutics Announces Results from Annual General Meeting

May 26, 2022: Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update 

May 11, 2022: Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas

April 27, 2022: Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Update

April 12, 2022: Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR)

March 30, 2022: Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas

March 09, 2022: Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)

February 21, 2022: Rakovina Therapeutics preventing cancer cells from making DNA repairs they need to survive

January 25, 2022: Rakovina Therapeutics President to Join Expert Panel at the Fifth Annual DDR, ATR & PARP Inhibitors Summit

January 06, 2022: Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022

December 21, 2021: Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents

November 23, 2021: Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results and Provides Corporate Update

November 16, 2021: Rakovina Therapeutics Partners with St. Baldrick’s Foundation to Research and Develop New Treatments for Childhood Bone Cancer

November 11, 2021: Rakovina Therapeutics Presents at the 6th biennial Canadian Cancer Research Conference

October 21, 2021: Rakovina Therapeutics to Present at the 6th biennial Canadian Cancer Research Conference

October 12, 2021: Rakovina Therapeutics Presents at the 2021 AACRNCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

October 7, 2021: Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series PARP Inhibitors

September 16, 2021: Rakovina Therapeutics Presents Preclinical Data on novel kt-3000 Series Drug Candidates at JCA-AACR Precision Medicine International Conference 

September 9, 2021: Rakovina Therapeutics to Present at the JCA-AACR Precision Medicine International Conference 

August 26, 2021: Rakovina Therapeutics Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update

August 17, 2021: Rakovina Therapeutics to Present at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

June 29, 2021: Rakovina Therapeutics Announces Results from Annual General Meeting

June 17, 2021: Rakovina Therapeutics to Present at at The Emerging Growth Conference on June 23, 2021

May 27, 2021: Rakovina Therapeutics Inc. Announces First Quarter 2021 Financial Results and Provides Corporate Update

April 29, 2021: Rakovina Therapeutics Inc. Announces Inaugural Scientific Advisory Board

April 8, 2021: Rakovina Therapeutics Inc. Receives European and Canadian Patents on kt-2000 series PARP-inhibitors

April 5, 2021: Rakovina Therapeutics Inc. Appoints Biotechnology Industry Veteran Julie M. Cherrington, PhD to Board of Directors

April 1, 2021: Rakovina Therapeutics Inc. Commences Trading on TSX Venture Exchange Under Ticker Symbol “RKV”

March 25, 2021: Rakovina Therapeutics Inc. (Formerly Vincero Capital Corp.) Announces Closing of Qualifying Transaction

March 19, 2021: Vincero Capital Corp. Announces Filing of Filing Statement in Connection with Qualifying Transaction

March 12, 2021:  Vincero Capital Corp. Receives Conditional Approval of TSX Venture Exchange for Qualifying Transaction with NewGen Therapeutics, Inc. and Announces Over-Subscribed Financing

November 10, 2020:  Vincero Capital Provides Update on Qualifying Transaction